Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage oncology company focused on overcoming drug resistance and immune suppression in cancer, announced that its CEO and Chairman Dr. John Yu will present at the 16th Annual LD Micro Invitational on May 18, 2026. The presentation, scheduled for 1:00 p.m. PDT at the Luxe Sunset Boulevard Hotel in Los Angeles, will provide an update on the company's clinical program and partnering activities.
The presentation comes at a pivotal time for Kairos Pharma as it advances its lead candidate, ENV-105, an antibody targeting CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is designed to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is being evaluated in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs in these patient populations.
The LD Micro Invitational is a prominent investor conference that brings together emerging growth companies and the investment community. Kairos Pharma's participation underscores the company's commitment to communicating its progress and strategic direction to potential partners and investors. The company's focus on structural biology to develop therapeutics that overcome resistance mechanisms is particularly relevant given the challenges in treating cancers that become resistant to standard therapies.
Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics. ENV-105 aims to target CD105, which has been linked to drug resistance and disease relapse. By neutralizing this protein, the therapy could potentially restore the efficacy of existing treatments, offering new hope for patients with limited options. The Phase 2 trial in castrate-resistant prostate cancer and the Phase 1 trial in non-small cell lung cancer are critical steps in evaluating the safety and efficacy of ENV-105.
It is important to note that, as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The outcomes of these clinical trials will be crucial in determining the future regulatory path and potential market availability of the therapy.
The announcement of Dr. Yu's presentation at the LD Micro Invitational provides an opportunity for investors and industry observers to gain insights into Kairos Pharma's clinical progress and strategic initiatives. The company's efforts to address drug resistance in cancer could have significant implications for the oncology field, potentially leading to improved outcomes for patients who have exhausted standard treatment options.
For more information about Kairos Pharma, including the latest news and updates, visit the company's newsroom at https://ibn.fm/KAPA. The full press release regarding the presentation can be accessed at https://ibn.fm/g3aQY.
